CABANA Trial
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation
Inclusion criteria
- Have documented AF episodes >two episodes over four months with electrocardiographic documentation of one episode or at least one episode of AF lasting more than one week
- Warrant active therapy beyond simple ongoing observation
- Be eligible for catheter ablation and >two sequential rhythm control and/or >three rate control drugs
- Be >65 years of age, or <65 years with one or more of the following risk factors for stroke:
- Diabetes
- Congestive heart failure (including systolic or diastolic heart failure)
- Prior stroke or TIA
- LA size >5.0cm (or volume index >44cc/m2) or EF<35
- Subjects <65 years of age whose only risk factor is hypertension must have a second risk factor or LV hypertrophy to qualify
Exclusion criteria
- Lone AF in absence of risk factors for stroke in patients <65 years of age
- Patients who in the opinion of managing clinician should not yet receive any therapy for AF
- Patients who have failed >two membrane active anti-arrhythmic drugs at a therapeutic dose due to inefficacy or side effects
- More than one week of amiodarone treatment in the past three months
- An efficacy failure of full-dose amiodarone treatment >12 weeks duration at any time
Principal investigator: Blair Halperin, M.D.
Sponsor: National Heart Lung and Blood Institute (NHLBI)
Contact: Heather Aiona, CCRC, clinical research coordinator, 503-216-2099
ST. JUDE QUICK FLEX Registry
QuickFlex® Model 1258T Left Heart Pacing Lead Post Approval Study: CRT-D (Cardiac Resynchronization Therapy Defibrillator)
Sponsor: St. Jude Medical
Principal investigator: Alexi Zemsky, M.D.
Contact: Jan Coan, CCRC, study coordinator, 503-963-3026